SCHEMBL273222

SCHEMBL273222

COc1ccc(C(=O)Nc2ccc(Cl)cc2C(=O)N/N=C/c2ccc(Cl)c(C(F)(F)F)c2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.54
PKM P14618 2/20 0.54
NPC1 O15118 2/20 0.54
MAPT P10636 8/20 0.52
KDM4E B2RXH2 5/20 0.51
OPRK1 P41145 1/20 0.51
HTT P42858 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 5/20 0.49
POLB P06746 4/20 0.49
HPGD P15428 2/20 0.48
USP2 O75604 1/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ADCYAP1R1 P41586 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265414 1.00 RAB9A (0.54) RAB9APKMNPC1MAPTKDM4E
SCHEMBL265415 1.00 RAB9A (0.54) RAB9APKMNPC1MAPTKDM4E
SCHEMBL267831 0.92 RAB9A (0.53) RAB9APKMNPC1MAPTKDM4E
SCHEMBL267830 0.92 RAB9A (0.53) RAB9APKMNPC1MAPTKDM4E
SCHEMBL273397 0.92 RAB9A (0.53) RAB9APKMNPC1MAPTKDM4E
SCHEMBL265345 0.92 RAB9A (0.52) RAB9APKMNPC1MAPTKDM4E
SCHEMBL265346 0.92 RAB9A (0.52) RAB9APKMNPC1MAPTKDM4E
SCHEMBL273842 0.92 RAB9A (0.52) RAB9APKMNPC1MAPTKDM4E
SCHEMBL268356 0.91 RAB9A (0.66) RAB9APKMNPC1MAPTKDM4E
SCHEMBL273540 0.91 RAB9A (0.66) RAB9APKMNPC1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885PKM 1916/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.